| Name | Title | Contact Details |
|---|
Magnolia Neurosciences Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines.
Orphan Star Therapeutics, LLC, a biopharmaceutical company, develops therapies for rare genetic diseases including Canavan disease, glut1 deficiency, and rare genetic skin diseases.
Neova Technologies Inc. is a Abbotsford, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.
Civetta Therapeutics was founded by William Sellers (Broad Institute and Dana-Farber Cancer Institute) and Eric Fischer (Dana Farber Cancer Institute and Harvard Medical School) to advance new medicines through small molecule intervention targeting propeller domains with the goal of developing important therapeutics for cancer and other indications.